G
Guido Dalbagni
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 282
Citations - 19188
Guido Dalbagni is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Bladder cancer & Cystectomy. The author has an hindex of 69, co-authored 254 publications receiving 16962 citations. Previous affiliations of Guido Dalbagni include Cornell University & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Epidemiology and risk factors of urothelial bladder cancer
Maximilian Burger,James W.F. Catto,Guido Dalbagni,H. Barton Grossman,Harry W. Herr,Pierre I. Karakiewicz,Wassim Kassouf,Lambertus A. Kiemeney,Carlo La Vecchia,Shahrokh F. Shariat,Yair Lotan +10 more
TL;DR: UBC is a frequently occurring malignancy with a significant impact on public health and will remain so because of the high prevalence of smoking and the importance of primary prevention must be stressed and smoking cessation programs need to be encouraged and supported.
Journal ArticleDOI
Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology
Ahmad Shabsigh,Ruslan Korets,Kinjal C. Vora,Christine M. Brooks,Angel M. Cronin,Caroline O. S. Savage,Ganesh V. Raj,Bernard H. Bochner,Guido Dalbagni,Harry W. Herr,S. Machele Donat +10 more
TL;DR: Surgical morbidity following radical cystectomy is significant and, when strict reporting guidelines are incorporated, higher than previously published.
Journal ArticleDOI
Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update
M. Craig Hall,Sam S. Chang,Guido Dalbagni,Raj S. Pruthi,John D. Seigne,Eila C. Skinner,J. Stuart Wolf,Paul F. Schellhammer +7 more
TL;DR: The AUA’s PGC elected to update the initial report by appointing a panel to develop a new guideline for the management of nonmuscle invasive bladder cancer founded on evidence-based outcomes in the literature as well as expert opinion.
Journal ArticleDOI
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.
Harry W. Herr,Bernard H. Bochner,Guido Dalbagni,S. Machele Donat,Victor E. Reuter,Dean F. Bajorin +5 more
TL;DR: In this article, the number of lymph nodes examined in cystectomy specimens can have an impact on the outcome of patients with bladder cancer and the local recurrence rate and survival outcome.
Journal ArticleDOI
Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease Progression
Alvaro S. Sarkis,Guido Dalbagni,Carlos Cordon-Cardo,Zuo-Feng Zhang,Joel Sheinfeld,William R. Fair,Harry W. Herr,Victor E. Reuter +7 more
TL;DR: The results suggest that T1 bladder cancers exhibiting nuclear overexpression of p53 protein have a higher probability of disease progression and suggests that p53 overeexpression is an important prognostic factor in these patients and may be useful in selecting appropriate therapy.